Success Metrics

Clinical Success Rate
67.2%

Based on 41 completed trials

Completion Rate
67%(41/61)
Active Trials
35(31%)
Results Posted
124%(51 trials)
Terminated
20(18%)

Phase Distribution

Ph phase_3
15
13%
Ph not_applicable
17
15%
Ph early_phase_1
3
3%
Ph phase_1
29
26%
Ph phase_2
46
41%

Phase Distribution

32

Early Stage

46

Mid Stage

15

Late Stage

Phase Distribution110 total trials
Early Phase 1First-in-human
3(2.7%)
Phase 1Safety & dosage
29(26.4%)
Phase 2Efficacy & side effects
46(41.8%)
Phase 3Large-scale testing
15(13.6%)
N/ANon-phased studies
17(15.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

62.1%

41 of 66 finished

Non-Completion Rate

37.9%

25 ended early

Currently Active

35

trials recruiting

Total Trials

112

all time

Status Distribution
Active(38)
Completed(41)
Terminated(25)
Other(8)

Detailed Status

Completed41
Terminated20
Active, not recruiting18
Recruiting17
unknown8
Withdrawn5

Development Timeline

Analytics

Development Status

Total Trials
112
Active
35
Success Rate
67.2%
Most Advanced
Phase 3

Trials by Phase

Early Phase 13 (2.7%)
Phase 129 (26.4%)
Phase 246 (41.8%)
Phase 315 (13.6%)
N/A17 (15.5%)

Trials by Status

recruiting1715%
terminated2018%
unknown87%
not_yet_recruiting33%
withdrawn54%
active_not_recruiting1816%
completed4137%

Recent Activity

Clinical Trials (112)

Showing 20 of 112 trialsScroll for more
NCT05946213Phase 3

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Recruiting
NCT03070886Phase 2

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Completed
NCT07061977Phase 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Recruiting
NCT04423211Phase 3

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Recruiting
NCT07195591Phase 3

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

Recruiting
NCT02595879Phase 1

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Active Not Recruiting
NCT01507428Phase 2

Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer

Completed
NCT03942328Phase 1

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Recruiting
NCT07528352Phase 1

External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL

Not Yet Recruiting
NCT03786783Phase 2

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Active Not Recruiting
NCT02306161Phase 3

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Active Not Recruiting
NCT04214067Phase 3

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Active Not Recruiting
NCT02466971Phase 3

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Active Not Recruiting
NCT05570422Phase 1

A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01

Recruiting
NCT03543189Phase 1

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

Active Not Recruiting
NCT03197506Phase 2

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Active Not Recruiting
NCT02422498Phase 2

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

Active Not Recruiting
NCT06323460Phase 2

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

Recruiting
NCT05477823Early Phase 1

Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer

Active Not Recruiting
NCT02515110Not Applicable

Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer

Active Not Recruiting

Drug Details

Intervention Type
RADIATION
Total Trials
112